Results 71 to 80 of about 4,550 (156)
Stimuli‐responsive systems: A focus on controlled drug delivery for posterior segment ocular disease
Responsive Materials, Volume 3, Issue 4, November 2025.This review highlights recent advances in stimuli‐responsive drug delivery for posterior segment diseases, focusing on mechanisms and potential. It also explores mechanically interlocked molecules and bioorthogonal reactions as novel approaches. Challenges and future perspectives are discussed, aiming to bridge the gap between research and clinical ...
Chengzhi Zhang +11 more
wiley +1 more source
Toxins, 2017 Immunotoxins (ITs) are hybrid proteins combining the binding specificity of antibodies with the cytocidal properties of toxins. They represent a promising approach to lymphoma therapy. The cytotoxicity of two immunotoxins obtained by chemical conjugation
Letizia Polito +6 more
doaj +1 more source
European Journal of Neuroscience, Volume 62, Issue 9, November 2025.The measurement of choline as a biomarker for in vivo cholinergic neurotransmission is a valuable tool in the study of a range of CNS disorders. However, the continuous detection of cholinergic neurotransmission in selective brain regions in the mouse brain remains challenging and underexploited.
Seán Doyle +3 more
wiley +1 more source
Bacterial Toxins for Cancer Therapy
Toxins, 2017 Several pathogenic bacteria secrete toxins to inhibit the immune system of the infected organism. Frequently, they catalyze a covalent modification of specific proteins. Thereby, they block production and/or secretion of antibodies or cytokines. Moreover,
Nour-Imene Zahaf, Gudula Schmidt
doaj +1 more source
Cancer Reports, Volume 8, Issue 10, October 2025.ABSTRACT Background Hairy cell leukemia (HCL) is a rare disorder characterized by splenomegaly, pancytopenia, and proliferation with “hairy” lymphocytes. Treatment is based on purine analogs and anti‐CD20 antibodies, often resulting in significant adverse effects.
M. Garcia Fasanella +4 more
wiley +1 more source
Antibodies, 2013 Elucidating the intracellular fate(s) of targeted toxins is of fundamental importance for their optimal use as anticancer drugs, since the biochemical targets of their enzymatic activity reside in the cell cytoplasm, as in the case of the plant ribosome ...
Maria Serena Fabbrini +6 more
doaj +1 more source
Countering immunotoxin immunogenicity [PDF]
British Journal of Cancer, 2016 The entry of antibody-based drugs into mainstream medicine has provided the oncologist with new therapeutic tools that have begun to transform the treatment of cancer (Scott et al, 2012; Lee et al, 2013). Toxicity profiles and cell killing mechanism(s) exhibited by antibody and small-molecule cytotoxic therapies are largely non-overlapping, thus ...
openaire +2 more sources
Immunotoxins: The Role of the Toxin
Toxins, 2013 Immunotoxins are antibody-toxin bifunctional molecules that rely on intracellular toxin action to kill target cells. Target specificity is determined via the binding attributes of the chosen antibody. Mostly, but not exclusively, immunotoxins are purpose-
David FitzGerald, Antonella Antignani
doaj +1 more source
Fungal Ribotoxins: A Review of Potential Biotechnological Applications
Toxins, 2017 Fungi establish a complex network of biological interactions with other organisms in nature. In many cases, these involve the production of toxins for survival or colonization purposes. Among these toxins, ribotoxins stand out as promising candidates for
Miriam Olombrada +8 more
doaj +1 more source
Site-Specific PEGylation of Recombinant Immunotoxin DAB389IL-2: Structural and Functional Assessment
Research in Molecular Medicine, 2019 Background: DAB389IL-2 is considered a fusion immunotoxin and it is used for the CTCL therapy. DAB389IL-2 includes of two distinct portions; the catalytic domain of diphtheria toxin and IL-2. DAB389IL-2 duo to the presence of a free cysteine residue (Cys
Nasrin Zarkar +5 more
doaj